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Abstract
BACKGROUND—Neural tube defects (NTDs) occur in as many as 0.5–2 per 1000 live births in
the United ‘States. One of the most common and severe neural tube defects is meningomyelocele
(MM) resulting from failed closure of the caudal end of the neural tube. MM has been induced by
retinoic acid teratogenicity in rodent models. We hypothesized that genetic variants influencing
retinoic acid (RA) induction via retinoic acid receptors (RARs) may be associated with risk for
MM.
METHODS—We analyzed 47 single nucleotide polymorphisms (SNPs) that span across the three
retinoic acid receptor genes using the SNPlex genotyping platform. Our cohort consisted of 610
MM families.
RESULTS—One variant in the RARA gene (rs12051734), three variants in the RARB gene
(rs6799734, rs12630816, rs17016462), and a single variant in the RARG gene (rs3741434) were
found to be statistically significant at p < 0.05.
CONCLUSION—RAR genes were associated with risk for MM. For all associated SNPs, the rare
allele conferred a protective effect for MM susceptibility.
Keywords
retinoic acid receptor genes; meningomyocele; association studies; single nucleotide
polymorphisms (SNPs)
INTRODUCTION
Neural tube defects (NTDs) are congenital defects that result from the malformation of the
brain and spinal cord. NTDs are severely disabling and occur in 0.5–2 per 1000 pregnancies
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in the United States (Greene et al., 2009; Copp and Greene, 2010). One of the most common
and severe among these neural tube defects is meningomyelocele (MM). MM results from
failed closure of the caudal end of the neural tube during the first month of pregnancy. This
incomplete formation results in exposure of the spinal cord and meninges (tissue covering
the spinal cord). Surgical treatment to prevent infection and further damage to the spinal
cord is available within the affected infant's first 24 to 48 hours of life. Despite corrective
surgery, children with MM will likely need addition medical care, physical therapy, and
remediation to overcome learning disabilities (Fletcher et al., 2005)
Although the exact cause remains unknown, the etiology of MM is linked to both genetic
and environmental components. To better understand the pathophysiology of MM, rodent
models have provided useful information (Juriloff and Harris, 2000; Harris and Juriloff,
2007). Vita-min A and its biologically active metabolite retinoic acid (RA) have been
implicated in neuronal differentiation and neural tube patterning (Maden, 2006). Low
dosage administration of RA has been found to reduce the incidence of spinal NTDs in
mouse models (Wilson et al., 2003; Maden, 2006). Conversely, RA when administered in
teratogenic doses has been known to induce MM in several different rodent species (Danzer
et al., 2005; Harris and Juriloff, 2007; Quemelo et al., 2007). These observations suggest
that MM susceptibility could be associated with the genes in the RA signaling pathways.
The effects of RA are mediated by two classes of ligand-dependent transcription factors, the
retinoic acid receptors (RARs) and the retinoid X receptors (RARs). RARs are nuclear
family receptor members that are bound and activated by both all-trans-RA and 9-cisRA,
whereas only 9-cisRA activates RXRs (Mao and Collins, 2002; Zechel, 2005). Together
RARs and RXRs interact to form heterodimers, later binding to RA response elements to
regulate transcription of genes (Matt et al., 2003). There are three RAR genes, designated
RARA, RARB, and RARG, each located on different chromosomes. With differing expression
and localization patterns, it has been suggested that the three RAR genes are functionally
distinct (Leroy et al., 1991). To further the complexity, RARA and RARG each have two
major isoforms, whereas RARB has four distinct isoforms, resulting in a large potential of
regulatory proteins and transcriptional functions.
We hypothesized that genetic variants influencing RA induction via RARs may be
associated with risk for MM. We analyzed 47 single nucleotide polymorphisms that span
across the three RAR genes and their association with MM.
MATERIALS AND METHODS
All experimental protocols were approved by the Committees for the Protection of Human
Subjects at the University of Texas Health Science Center at Houston. Sites for subject
enrollment included the Shriners Hospital for Children at Houston, Texas; the Shriners
Hospital for Children at Los Angeles, California; the Shriners Hospital for Children at
Lexington, Kentucky; Texas Children's Hospital, Houston, Texas; and the Hospital for Sick
Kids, Toronto, Canada.
Patients with MM and their parents were enrolled in the study from 1996 to 2006 (Au et al.,
2008). The tested samples comprised 329 affected family trios and 281 affected family duos.
Trios included affected child and both parents, and duos included the affected child and only
a single parent. Table 1 describes the ethnicity and sex of the probands tested. Ninety-two
Hispanic individuals were recruited locally, and 92 Caucasian individuals were selected
from the HD100CAU (Corriell Institute, Camden, NJ) to serve as genotyping controls.
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DNA Collection and Preparation
Whole blood samples and/or saliva samples were collected from patients with MM and both
parents when possible. Genomic DNA was extracted from blood using the Puregene DNA
extraction Kit (Quiagen, Valencia, CA) and saliva using the Oragene DNA Collection Kit
from DNA Genotek (Ontario, Canada).
SNPlex Genotyping
Single nucleotide polymorphism (SNP) genotyping was performed using the SNPlex
Genotyping system (Applied Biosystems, Foster City, CA). The system is based on
oligonucleotide ligation/polymerase chain reaction and capillary electrophoresis to
simultaneously analyze up to 48 SNPs (Tobler et al., 2005). SNPs were selected (Table 2)
and submitted through the SNPlex Assay Design pipeline to generate probe pools (Davidson
et al., 2008; Martinez et al., 2009). Experiments were carried out according to ABI Standard
SNPlex protocol. Two hundred nanograms of working DNA was used for each of the
SNPlex reactions on Dual 384 well block ABI 9700s. Capillary electrophoresis of the
SNPlex products was subsequently carried out on the ABI 3730 XL genetic analyzer. Data
analysis was performed using GeneMapper version 4.0 software (Blue Heron, Bothell, WA).
Genotype calls were evaluated independently by at least two investigators to ensure
consistency.
Our criteria required SNPs to have at least an 85% genotype call rate. Genotypes were tested
for Mendelian inheritance errors. SNPs with more than 1.6% (10/610) of families showing
Mendelian errors were excluded (Martinez et al., 2009). To ensure SNPlex genotyping call
accuracy, we included 84 CEPH individuals used in the Hapmap project. One hundred
percent concordance was observed between the CEPH sample genotype results and
genotypes published in the dbSNP NCBI database (GRCh37/hg19).
Statistical Analysis
Allele frequencies, Hardy-Weinberg equilibrium, and our triad-based association analyses
were performed using a transmission disequilibrium test (TDT) in the PLINK v1.07
(http://pngu.mgh.harvard.edu/purcell/plink/) whole genome association analysis toolset
(Purcell et al., 2007).
RESULTS
Of the 47 genotyped SNPs, two SNPs (one in RARA and one in RARB) failed to meet the
quality control criteria and were excluded from further statistical analyses. Minor allele
frequencies were calculated for the remaining 45 SNPs in Caucasian and Hispanic controls
and are presented in Table 2.
Five SNPs were statistically significantly associated with MM (p < 0.05) (Table 3). All five
statistically significant SNPs were in Hardy-Weinberg equilibrium, and none were in
linkage disequilibrium when analyzed using Haploview software version 4.2 (Barrett et al.,
2005). Even after correction for false positives by Bonferroni (1/45 expected false positives;
p < 0.022222), all five SNPs remained significant.
Of the five SNPs tested in the RARA gene, only one (rs12051734) located in intron 2 of the
longest transcription isoform (NM_000964.3) was found to be statistically significant with
MM (p = 0.01496). Three SNPs (rs6799734, rs12630816, and rs17016462) of the 32 tested
in the RARB gene demonstrated association with MM. Two of these SNPs, rs6799734 and
rs17016462, are located in intron 1 and intron 2, respectively, of the longest transcription
isoform (NM_000965.3) of RARB. The TDT analysis yielded a p value of 0.005459 for
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rs6799734 and of 0.01954 for rs17016462. Rs12630816 (p = 0.000546) is a variant ~2 kbp
upstream in the promoter region of RARB. Finally, among the eight SNPs tested in the
RARG gene, only one (rs3741434) in the common 3′-untranslated region (3′-UTR) of all
transcription isoforms was shown to be highly associated with MM (p = 0.000246). A
summary of the five significant SNPs along with their gene location and p values is shown
in Table 3.
DISCUSSION
To our knowledge, this is the first study to investigate association of RAR genes with MM in
humans. In our study of 610 MM families, we identified five significant SNPs among the
three RAR genes that demonstrate association with MM. All five SNPs that met our
threshold for significance of p < 0.05 remained significant after Bonferroni testing for
multiple comparisons. For all associated SNPs, the rare allele conferred a protective effect
for MM susceptibility. Our findings are consistent with existing animal models that the RAR
genes are associated with the development of MM.
The most significant result we found was that rs3741434, located in the 3′-UTR of both
transcription isoforms of RARG, is significantly associated with MM risk. This finding,
coupled with evidence from animal models, provides additional support that RA receptors,
specifically RARG, could play a functional role to the etiology of MM.
Expression of Rarg during neural tube formation has been studied in the curly tail (ct)
mouse, a classic model for human neural tube defects. Mouse mutants that are homozygous
ct/ct develop spinal NTDs in more than 50% of cases (Maden, 2006). RA treatment at a
specific time point in development prevents the ct/ct phenotype by enhancing posterior
neuropore closure (Chen et al., 1994). In addition, in situ hybridization studies have shown
that Rarg transcripts are deficient in the ct mutants and are up-regulated in the posterior
neuropore following low-dose RA treatment (Chen et al., 1995).
Loss of Cyp26A1 function is embryonic lethal and produces a phenotype that mimics RA-
induced spina bifida (SB) (Abu-Abed et al., 2001). Cytochrome P450 (CYP26) enzymes are
responsible for the inactivation of RA. The catabolic activity of CYP26A1 affects the
available amount of RA throughout embryonic development. For this reason, Rat et al.
(2006) screened coding sequences of the RA-metabolizing enzyme gene CYP26A1 for
mutation among 40 Italian SB patients and 40 healthy French “controls.” They found no
evidence for involvement of CYP26A1 in the pathogenesis of SB for their population. Their
study was limited by small sample size and could have missed an association. Further, the
finding does not surprise us because of the distinct functions of CYP26A1 (regulating the
amount of RA available) versus RARs (transcription factors that activate RA responsive
genes), nor does it weaken the conclusion of our results regarding the potential role of the
RAR genes in MM susceptibility. When Cyp26A1 null mutants are crossed with Rarg null
mutants, the resulting double-knockout animals display normal gene expression patterns.
Surprisingly, the lethal effects of the Cyp26A1 null mutant are rescued when compounded
with the loss of Rarg (Abu-Abed et al., 2003).
Another study (Deak et al., 2005) used the PCR sequencing method to screen coding
sequences of five genes involving RA metabolism (ALDH1A2, CYP26A1, CYP26B1,
CRABP1, and CRABP2) for mutation among 78 pooled samples of 230 SB patients and then
genotyped 318 simplex and multiplex patient families for disease association analysis. The
study concluded that several SNPs in the ALDH1A2 gene associated with increased risk for
lumbosacral myelomeningocele in humans. ALDH1A2 (also known as RALDH2) is the
primary enzyme responsible for converting retinol to retinoic acid. However, the most
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significant association was observed with a synonymous SNP (pA151A, c.453A>G) with a
rare allele frequency that is extremely small, suggesting that the risk allele affects only a
small portion of the patient population. The functional significance of the finding is not
known. This is a larger study but does not directly address association of RARs to human
MM. Our findings are consistent with the conclusion of this study.
The individual null Rara, Rarb, Rarg mice are viable and have shown mild to no phenotypic
changes as a result of the ablations. Redundancy of the three RA receptors present in the
genome may be a contributing factor for these observations. However, the Rarg null mutant
when compared to the wild type shows complete resistance to RA-induced SB (Lohnes et
al., 1993). In addition to the single null Rar mutants, double knockout mutants lacking two
Rar isotypes have been studied, and these double mutants are embryonic lethal or
postpartum lethal because of severe developmental defects (Mark et al., 2009).
In the largest of the three RAR genes evaluated, RARB, we identified three SNPs located in
the promoter and introns 1 and 2 that show association with MM. The RARB gene is
approximately 170 kbp long located at human chromosomal region 3q24.2. Twenty-three
SNPs downstream spanning ~152 kbp of RARB were also evaluated, but no association was
identified. In general, transcription regulatory sites are commonly located in the promoter
and the first few introns of genes. Further experiments are needed to determine whether a
specific allele of the associated SNPs affect transcription of RARB. The association of
rs17016462 in intron 2 of RARB should be approached with caution due to its low MAF
(0.02) within our Caucasian control group.
Rs12051734 associated with MM is located in intron 2 of the RARA gene. In silico analysis
was performed on the significant SNPs using the Human Splicing Finder version 2.4 website
to predict possible changes to mRNA splicing (Desmet et al., 2009). Within the RARA gene,
when compared to the wild-type reference sequence, the T variant of intronic SNP
rs12051734 was found to potentially disrupt splice site motifs. No other significant splicing
predictions were found among the other four associated SNPs.
The strengths of our study include our relatively large cohort of 610 families, which is
complemented by the use of the family-based TDT method. In addition, our sample set
consists of two major affected ethnic groups: Hispanics and Caucasian, as well as two
ethnically matched control groups. Among our 45 SNPs, 40 SNPs did not reach nominal
significance. In addition to the five SNPs that were associated in our population as a whole,
there were two SNPs (rs1465057 and rs6580936, both in the RARG gene) that were
significantly associated only in our subset of Hispanic families and two other SNPs
(rs1153594 and rs2715553 in the RARB and RARA genes, respectively) that were
significantly associated only our subset of Caucasian American families. We view these
results with caution because of the small sample size when separately analyzing the ethnic
groups. A limitation is that the tested SNPs represent a small fraction of the known SNPs
spanning the RAR genes.
Although we found SNPs among the three RAR genes to be associated with MM, the
specific mechanism by which the RAR genes influence MM susceptibility remains unknown.
MM is a complex disorder that occurs as a result of both genetic factors and the
environment. To add further complexity, RA contribution to MM varies not only spatially,
but also temporally. This study suggests that changes in RAR function may play a role in
MM susceptibility. Further validation studies on an independently ascertained MM cohort,
as well as functional investigation of the retinoic acid receptors, are warranted.
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Table 1
Study Population
Characteristic Trios Duos Total
Ethnicity
 Caucasian 142 84 226
 Hispanic 168 166 334
 African American 4 14 18
 Asian American 2 2 4
 Other 7 5 12
 Unreported 6 10 16
 Total 329 281 610
Sex
 Male 155 129 284
 Female 174 152 326
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